{"id":65063,"date":"2026-05-12T15:13:42","date_gmt":"2026-05-12T07:13:42","guid":{"rendered":"https:\/\/flcube.com\/?p=65063"},"modified":"2026-05-12T15:13:43","modified_gmt":"2026-05-12T07:13:43","slug":"akari-therapeutics-partners-with-wuxi-xdc-to-advance-novel-ph1-payload-platform-for-urothelial-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65063","title":{"rendered":"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer"},"content":{"rendered":"\n<p><strong>Akari Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AKTX:NASDAQ\">NASDAQ: AKTX<\/a>), the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with <strong>WuXi XDC<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2268:HKG\">HKG: 2268<\/a>), the leading global end-to-end <strong>CRDMO<\/strong> (Contract Research, Development and Manufacturing Organization). The collaboration aims to accelerate the development of Akari&#8217;s proprietary <strong>PH1 payload platform<\/strong>, with initial focus on <strong>AKTX-101<\/strong> for <strong>metastatic urothelial cancer<\/strong> in second-line treatment settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Biotech Partner<\/strong><\/td><td>Akari Therapeutics (US\/UK dual headquarters)<\/td><\/tr><tr><td><strong>CRDMO Partner<\/strong><\/td><td>WuXi XDC (HKG: 2268)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Novel PH1 payload platform<\/td><\/tr><tr><td><strong>Lead Candidate<\/strong><\/td><td>AKTX-101<\/td><\/tr><tr><td><strong>Initial Indication<\/strong><\/td><td>Metastatic urothelial cancer (second-line setting)<\/td><\/tr><tr><td><strong>Partnership Scope<\/strong><\/td><td>End-to-end development support leveraging WuXi XDC&#8217;s integrated capabilities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-unmet-need\">Product Profile &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Area:<\/strong> Metastatic urothelial cancer \u2013 second-line treatment<\/li>\n\n\n\n<li><strong>Clinical Gap:<\/strong> Limited effective options beyond standard chemoradiotherapy after first-line failure<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> Chemoradiotherapy offering minimal clinical benefit in refractory metastatic disease<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Estimated 30,000+ annual cases in major markets with poor prognosis post-first-line failure<\/li>\n\n\n\n<li><strong>Technology Innovation:<\/strong> PH1 payload platform designed to enhance therapeutic index and tumor targeting<\/li>\n\n\n\n<li><strong>Development Strategy:<\/strong> AKTX-101 serves as proof-of-concept for broader PH1 platform applications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>CRDMO Selection<\/strong><\/td><td>WuXi XDC&#8217;s integrated capabilities span from early development through commercial manufacturing<\/td><\/tr><tr><td><strong>Platform Validation<\/strong><\/td><td>Success with AKTX-101 would validate PH1 payload for expansion to other oncology indications<\/td><\/tr><tr><td><strong>Global Development<\/strong><\/td><td>Dual US-UK structure facilitates international regulatory strategy and market access<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>Novel payload chemistry potentially addresses limitations of existing ADC technologies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The partnership leverages WuXi XDC&#8217;s comprehensive development infrastructure to de-risk and accelerate Akari&#8217;s novel payload platform, while providing a clear pathway to address significant unmet needs in urothelial cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Urothelial Cancer Market:<\/strong> Global market projected to reach $3.5 billion by 2030, driven by expanding treatment options and combination therapies<\/li>\n\n\n\n<li><strong>Second-Line Opportunity<\/strong> | Limited competition in refractory metastatic setting creates potential for premium positioning<\/li>\n\n\n\n<li><strong>Platform Value<\/strong> | PH1 payload technology could support multiple pipeline candidates across different tumor types<\/li>\n\n\n\n<li><strong>Development Timeline<\/strong> | Accelerated path to IND\/CTA expected through WuXi XDC&#8217;s integrated service model<\/li>\n\n\n\n<li><strong>Strategic Implications<\/strong> | Successful partnership may lead to expanded collaboration across Akari&#8217;s broader pipeline<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership arrangements, development timelines, clinical opportunities, and commercial expectations for Akari&#8217;s PH1 payload platform. Actual results may differ due to risks including preclinical\/clinical outcomes, regulatory decisions, competitive dynamics, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akari Therapeutics (NASDAQ: AKTX), the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4738,16,1183,4739,364],"class_list":["post-65063","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-akari-therapeutics","tag-cancer","tag-hkg-2268","tag-nasdaq-aktx","tag-wuxi-xdc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Akari Therapeutics, the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with WuXi XDC (HKG: 2268), the leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization). The collaboration aims to accelerate the development of Akari&#039;s proprietary PH1 payload platform, with initial focus on AKTX-101 for metastatic urothelial cancer in second-line treatment settings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65063\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer\" \/>\n<meta property=\"og:description\" content=\"Akari Therapeutics (NASDAQ: AKTX), the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with WuXi XDC (HKG: 2268), the leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization). The collaboration aims to accelerate the development of Akari&#039;s proprietary PH1 payload platform, with initial focus on AKTX-101 for metastatic urothelial cancer in second-line treatment settings.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65063\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T07:13:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T07:13:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65063#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65063\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer\",\"datePublished\":\"2026-05-12T07:13:42+00:00\",\"dateModified\":\"2026-05-12T07:13:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65063\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Akari Therapeutics\",\"Cancer\",\"HKG: 2268\",\"NASDAQ: AKTX\",\"WuXi XDC\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65063#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65063\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65063\",\"name\":\"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-12T07:13:42+00:00\",\"dateModified\":\"2026-05-12T07:13:43+00:00\",\"description\":\"Akari Therapeutics, the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with WuXi XDC (HKG: 2268), the leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization). The collaboration aims to accelerate the development of Akari's proprietary PH1 payload platform, with initial focus on AKTX-101 for metastatic urothelial cancer in second-line treatment settings.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65063#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65063\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65063#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Akari Therapeutics, the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with WuXi XDC (HKG: 2268), the leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization). The collaboration aims to accelerate the development of Akari's proprietary PH1 payload platform, with initial focus on AKTX-101 for metastatic urothelial cancer in second-line treatment settings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65063","og_locale":"en_US","og_type":"article","og_title":"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer","og_description":"Akari Therapeutics (NASDAQ: AKTX), the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with WuXi XDC (HKG: 2268), the leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization). The collaboration aims to accelerate the development of Akari's proprietary PH1 payload platform, with initial focus on AKTX-101 for metastatic urothelial cancer in second-line treatment settings.","og_url":"https:\/\/flcube.com\/?p=65063","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-12T07:13:42+00:00","article_modified_time":"2026-05-12T07:13:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65063#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65063"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer","datePublished":"2026-05-12T07:13:42+00:00","dateModified":"2026-05-12T07:13:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65063"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Akari Therapeutics","Cancer","HKG: 2268","NASDAQ: AKTX","WuXi XDC"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65063#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65063","url":"https:\/\/flcube.com\/?p=65063","name":"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-12T07:13:42+00:00","dateModified":"2026-05-12T07:13:43+00:00","description":"Akari Therapeutics, the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with WuXi XDC (HKG: 2268), the leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization). The collaboration aims to accelerate the development of Akari's proprietary PH1 payload platform, with initial focus on AKTX-101 for metastatic urothelial cancer in second-line treatment settings.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65063#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65063"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65063#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65063"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65063\/revisions"}],"predecessor-version":[{"id":65064,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65063\/revisions\/65064"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}